Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Mirum Pharmaceuticals (MIRM) Debt to Equity (2020 - 2023)

Mirum Pharmaceuticals has reported Debt to Equity over the past 4 years, most recently at $0.01 for Q1 2023.

  • Quarterly results put Debt to Equity at $0.01 for Q1 2023, down 57.86% from a year ago — trailing twelve months through Mar 2023 was $0.01 (down 57.86% YoY), and the annual figure for FY2022 was $0.01, down 53.78%.
  • Debt to Equity for Q1 2023 was $0.01 at Mirum Pharmaceuticals, up from $0.01 in the prior quarter.
  • Over the last five years, Debt to Equity for MIRM hit a ceiling of $0.02 in Q2 2021 and a floor of $0.01 in Q1 2021.
  • Median Debt to Equity over the past 4 years was $0.01 (2021), compared with a mean of $0.01.
  • Biggest five-year swings in Debt to Equity: surged 163.78% in 2022 and later plummeted 57.86% in 2023.
  • Mirum Pharmaceuticals' Debt to Equity stood at $0.01 in 2020, then soared by 126.07% to $0.02 in 2021, then tumbled by 53.78% to $0.01 in 2022, then rose by 0.63% to $0.01 in 2023.
  • The last three reported values for Debt to Equity were $0.01 (Q1 2023), $0.01 (Q4 2022), and $0.01 (Q3 2022) per Business Quant data.